Skip to main content

Table 1 Clinical characteristics of the randomized patient groups

From: Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis

Characteristic 977A 977B
  Number % Number %
Age at diagnosis (years)     
   ≤ 40 89 9 80 8
   41-50 197 20 207 21
   > 50 494 51 492 50
   unknown 197 20 198 20
Distant metastasis-free survival (years)     
   no recurrence, < 5 617 63 648 66
   recurrence, < 5 198 20 184 19
   lost to follow-up, < 5 111 11 96 10
   no recurrence, 5-to 10 245 25 253 26
   recurrence, 5 to 10 51 5 49 5
   lost to follow-up, 5 to 10 357 37 395 40
Estrogen receptor status     
   positive 657 67 686 70
   negative 220 23 181 19
   unknown 100 10 110 11
Lymph node status     
   negative 749 77 749 77
   positive 217 22 220 23
   unknown 11 1 8 1
Histologic grade     
   well differentiated 105 11 131 13
   moderately differentiated 317 31 335 34
   poorly differentiated 316 32 260 27
   unknown 239 24 251 26
Tumor size (cm)     
   ≤ 2.0 482 49 505 52
   2.1 to 5.0 363 37 356 36
   > 5.0 29 3 19 2
   unknown 103 11 97 10
Adjuvant treatment     
   yes 478 49 488 50
   no 490 50 484 50
   tamoxifen monotherapy (ER+) 318 33 332 34
   chemotherapy 141 14 140 14
   unknown 9 1 5 1
Molecular subtypes     
   Basal 243 25 217 22
   HER2-E 93 10 81 8
   Claudin-Low 48 5 44 5
   Luminal A 264 27 303 31
   Luminal B 185 19 188 19
  1. ER+: Estrogen receptor-positive breast cancer; HER2-E: human epidermal growth factor receptor 2-enriched.